No cell-related safety issues were encountered in this trial, although the patients receiving 18*10 6 MSCs showed a higher incidence of adverse effects ( Lastly, several human growth factor-based phase I/II clinical trials were started to evaluate the safety, tolerability, and preliminary effectiveness of intradiscal delivery of growth and differentiation factor-5 (GDF-5) as compared with placebo (sterile water/vehicle control) in human patients with early lumbar disc degeneration in the United States, Australia, and the Republic of Korea
In tumor cells, MK-2461 effectively restrained constitutive or ligand-induced phosphorylation of the juxtamembrane domain and COOH-terminal docking site of c-Met
(2019) Phytomedicines in the treatment of migraine
[DOI] [Google Scholar] 77.Sikiric P., Seiwerth S., Rucman R., Turkovic B., Rokotov D.S., Brcic L., Sever M., Klicek R., Radic B., Drmic D., et al
The typical duration for complete resumption of activity is generally observed to be between 2 and 3 weeks
The bottom line on human data: promising signals, no randomized controlled trials, and no long-term safety data in humans
